

Medicines Optimisation Prescribing Audit Schedule 2- Controlled Drug – Injections

Aim

The aim of this prescribing audit is to monitor the excessive amounts and/or unusual prescribing of controlled drug Schedule 2 injectables.

Rationale

Background

The monitoring of controlled drugs was a key recommendation from the Harold Shipman inquiry in January 2005. The Controlled Drugs (Supervision of Management and Use) Regulations 2006 (“the 2006 Regulations”) came into force on 1st January 2007 in England and 1 March 2007 in Scotland. As a consequence of the passing of the Health and Social Care Act 2012, these Regulations have been revised to reflect the new architecture for the NHS in England from April 2013. The Controlled Drugs (Supervision of Management and Use) Regulations 2013 (“the 2013 Regulations”) came into force in England and Scotland on 1st April 2013.¹

The Clinical Commissioning Group (CCG) has an obligation to monitor prescribing of controlled drugs under the Controlled Drugs (Supervision of management and use) Regulations 2013.¹

NHS England single operating model published November 2013² defines the roles and responsibilities of each organisation.

Unusual variations or significant high prescribing will be identified to target the audits in GP practices.

Examples of variations could include
(this list is not exhaustive)

- Higher prescribing per 1,000 patients than other GP practice within the CCG.
- Higher prescribing per 1,000 patients on particular injectable than other GP practices within the CCG.
- Significantly higher non-formulary injectable prescribing than other GP practices within the CCG.
- Unusual injectable prescribed.

Audit criteria

- Patient ID
- Patient surname
- Patient forename
- Patient DOB
- Registered or usual or prescribing GP [as per practice]
- Current drug search name
 - a) Alfentanil HCl_Inj 500mcg/ml 10ml Amp
 - b) Alfentanil HCl_Inj 500mcg/ml 2ml Amp
 - c) Alfentanil HCl_Inj 5mg/ml 1ml Amp
 - d) Diamorph HCl_Inj 100mg Amp
 - e) Diamorph HCl_Inj 100mg VI (Dry)
 - f) Diamorph HCl_Inj 10mg Amp
 - g) Diamorph HCl_Inj 10mg VI (Dry)
 - h) Diamorph HCl_Inj 30mg Amp
 - i) Diamorph HCl_Inj 30mg VI (Dry)
 - j) Diamorph HCl_Inj 500mg Amp
 - k) Diamorph HCl_Inj 500mg VI (Dry)
 - l) Diamorph HCl_Inj 5mg Amp
 - m) Diamorph HCl_Inj 5mg VI (Dry)
 - n) Ketamine_Inj 50mg/ml 10ml VI
 - o) Morph Sulf_Inj 10mg/1ml Amp
 - p) Morph Sulf_Inj 30mg/1ml Amp
 - q) OxyNorm_Inj 10mg/ml 1ml Amp
 - r) OxyNorm_Inj 10mg/ml 2ml Amp
 - s) Oxycodone HCl_Inj 10mg/ml 1ml Amp
 - t) Oxycodone HCl_Inj 10mg/ml 2ml Amp
 - u) Pethidine HCl_Inj 50mg/ml 1ml Amp
- Indication for starting schedule 2 injection
- Date of initiation
- GP who initiated Schedule 2 injection
- Quantity prescribed to date
- Intervals of prescription issued.
- Date of last review
- Pharmacist comments
- GP action

Method

Step 1: Medicines Optimisation Technician / pharmacist performs initial search in accordance with the audit criteria.

Step 2: Medicines Optimisation Pharmacist clinically reviews patients highlighted in search and recommends actions for the GP.

Step 3: Medicines Optimisation Team gives completed audit to GP practice team to either action or to be signed off to be actioned by Medicines Optimisation Team.

Step 4: Medicines Optimisation Team performs changes if required by GP practices.

Step 5 : Interventions captured and reported

Notes for Practice Pharmacist:

Any incidents must be reported to NHS England Shropshire & Staffordshire Area Team immediately
Contact details:

Controlled Drugs Accountable Officer , Samantha Travis Email address Samantha.travis@nhs.net



Controlled Drugs Support Officer (Shropshire & Staffordshire), Eleanor Carnegie Tel: 0113 8254630
Eleanor.carnegie@nhs.net

Reference:

1. Controlled Drugs (Supervision of management and use) Regulations 2013. Department of health 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/214915/15-02-2013-controlled-drugs-regulation-information.pdf

2. Single Operating Model. NHS England. November 2013
<https://www.england.nhs.uk/wp-content/uploads/2013/11/som-cont-drugs.pdf>

Appendices

Signature	Name	Title	Date
	Mrs Susan Bamford	Head of Medicine Optimisation	23. 3. 16.
	Dr Judith Crosse	East Staffs CCG Prescribing Lead	30. 3. 16.

